Corbevax Covid-19 Vaccine: The Central Drugs Standard Control Organisation has granted emergency use authorisation to COVID-19 vaccine, CORBEVAX for 12-18 year age group. The vaccine is India's 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against COVID-19.
The Subject Expert Committee (SEC) of the Drugs Controller General of India's had earlier recommended granting restricted emergency use approval to Biological E's COVID-19 vaccine, Corbevax, for use among adolescents aged between 12 to 18 years subject to certain conditions.
The SEC recommended emergency approval of Corbevax for vaccination of children only after reviewing its safety and immunogenicity data from the clinical study conducted on the children and adolescents.
Corbevax is a two-dose COVID-19 vaccine, which will be administered through intramuscular injection in a gap of 28 days just like Covaxin. It has been developed by the Hyderabad-based pharmaceutical company, Biological E.
Corbevax is a safe vaccine and local reactions are also less. The antibody level of this vaccine is also very high. Overall Corbevax is a very useful vaccine. It will have 2 primary doses just like other vaccines in India: Dr NK Arora, Chairman of COVID-19 Working Group of NTAGI https://t.co/yTA4a2gHPP pic.twitter.com/8hkBGHhF7d
— ANI (@ANI) February 15, 2022
Significance
Corbevax has become the second vaccine to receive emergency use approval in India for those aged below 18 years after Covaxin. The approval will speed up the ongoing vaccination drive for children aged between 15 and 18 years of age.
Corbevax vaccine: All you need to know!
• Corbevax is India’s first indigenously developed RBD protein sub-unit vaccine against Covid-19.
• The vaccine triggers an immune response by using fragments of the virus-like the spike protein, instead of using the whole virus.
• The vaccine contains a harmless S-protein antigen technology that binds to the Angiotensin-Converting Enzyme-2 (ACE2) receptor on the host cell membrane and enables virus entry.
• Once an individual's immune system recognises the S protein, it will produce antibodies as white blood cells to protect against the infection.
Corbevax Price
Corbevax vaccine is expected to cost around Rs 145 excluding taxes. The central government has reportedly already made an advance payment worth Rs 1,500 crore to reserve 30 crore doses of the Corbevax COVID-19 vaccine.
Background
India has administered both doses of COVID-19 vaccine to over 1.5 crore adolescents between the age group of 15 to 18 years. A total of 5,24,01,155 first doses and 1,63,10,368 second doses have been administered to the age group so far.
Comments
All Comments (0)
Join the conversation